01786nas a2200361   4500000000100000008004100001260001300042653002900055653002400084653004400108653001600152653003100168653001700199653001600216653001100232653002400243653002600267653001800293653002400311653002500335653002900360653003600389653001800425100001600443700001200459700001600471700001300487245009300500300001100593490000700604520079900611022001401410       1989                            d  c1989 Nov10aAntigen-Presenting Cells10aAntigens, Bacterial10aAntigens, Differentiation, T-Lymphocyte10aBCG Vaccine10aCD4-Positive T-Lymphocytes10aCD8 Antigens10aGlycolipids10aHumans10aIn Vitro Techniques10aLymphocyte Activation10aMycobacterium10aMycobacterium bovis10aMycobacterium leprae10aReceptors, Interleukin-210aStructure-Activity Relationship10aT-Lymphocytes1 aFournie J J1 aAdams E1 aMullins R J1 aBasten A00aInhibition of human lymphoproliferative responses by mycobacterial phenolic glycolipids.  a3653-90 v573 a<p>The effect of mycobacterial phenolic glycolipids from Mycobacterium leprae, M. bovis BCG, and M. kansasii on in vitro proliferative responses by human blood mononuclear cells from healthy BCG vaccinees was investigated. All three phenolic glycolipids inhibited proliferation in a concentration-dependent manner. Inhibition was independent of the stimulus used and involved neither antigen-presenting cells nor antigen-specific CD8+ suppressor T cells. It was concluded that the phenomenon may be a general property of mycobacterial phenolic glycolipids, perhaps analogous to the growth-modulating properties of gangliosides. Despite the lack of specificity of inhibition in vitro, de facto specificity may occur in vivo by virtue of the localization of glycolipid in the leprosy lesions.</p>  a0019-9567